A Study of Cognitive Health in Survivors of Prostate Cancer

Active, not recruiting

• Conditions: Survivorship; Prostate Cancer
• Interventions: Behavioral: PROMIS-SF v2.0 -Cognitive Function 8a

• Registration Number: NCT05540782
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to collect information that may help the researchers understand the relationship between prostate cancer survivors' experiences of cancer-related cognitive dysfunction (CRCD) and their other conditions (co-morbid factors), including anxiety, depression, and insomnia. The researchers will also find out how additional things may contribute to CRCD, including social factors, the characteristics of participants' prostate cancer, and the type of cancer treatment or other medications they received.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-08
• Study First Submitted: 2022-09-09
• Study First Submitted QC: 2022-09-13
• Study First Posted: 2022-09-15
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-14
• Last Update Posted: 2025-04-18
• Primary Completion: 2025-09-08
• Study Completion: 2025-09-08

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Male
• Target Recruitment: 200

Inclusion Criteria

• English-speaking
• Age 18 years or older
• History of histologically documented PC of any stage
• No evidence of PC Disease

Exclusion Criteria

• <1 month since completion of surgery, radiation, chemotherapy, or ADT
• Diagnosis of Alzheimer's disease, vascular dementia, Parkinson disease, or other organic brain disorder
• Score >10 indicative of dementia on Blessed Orientation Memory Concentration

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Survivors of Prostate Cancer	PROMIS-SF v2.0 -Cognitive Function 8a	This is a cross-sectional study with a one-time data collection process and no subsequent follow-ups. If patients did not opt out of receiving study-specific text communications, they may also receive text messages with reminders about surveys and/or direct links to REDCap to complete the surveys. Text-based communications will be delivered using the secure, HIPAA-compliant Mosio texting platform developed for clinical research.

Primary Outcome Measures

Name	Time	Method
number of participants with co-morbid symptoms	1 year	All participants will be evaluable as long as they have completed the PROMIS-SF v2.0 - Cognitive Function 8a.

Trial Locations

Locations (7)

Memorial Sloan Kettering Nassau; 🇺🇸 Uniondale, New York, United States

Memorial Sloan Kettering Bergen; 🇺🇸 Montvale, New Jersey, United States

Memorial Sloan Kettering Cancer Center Suffolk - Commack; 🇺🇸 Commack, New York, United States

Memorial Sloan Kettering Westchester; 🇺🇸 Harrison, New York, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

Memorial Sloan Kettering Basking Ridge; 🇺🇸 Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth; 🇺🇸 Middletown, New Jersey, United States